Suchen Protokolle in Revision. Zurück Neue Suche Zu den ErgebnissenErkrankungHauptgruppeBereichsübergreifend, Transplantation, zelluläre TherapieSolide TumorenProtokollgruppeGastroenterologische OnkologieGynäkologische OnkologieNeuroonkologieThorakale TumorenTumor, unabhängig von der EntitätViszeralchirurgieErkrankungLungenkarzinom, kleinzelligesLungenkarzinom, nichtkleinzelligesMagenkarzinomMammakarzinomMeningeosis neoplasticaOvarialtumorPeritonealkarzinose, sekundärTumor, verschiedene OrganeSubgruppeEpCAM positivER+ESR1-MutationgBRCA-MutationHER2+HER2-lowHER2-mutiertHER2-ultralowHR+HR+ postmenopausalHR+ prämenopausalPD-L1+PIK3CA/AKT1/PTEN-MutationenPIK3CA Mutationpostmenopausaltripel-negativunfitICD10C16.-C16.0C34.-C50.-C56C78.6C79.3MeSHBreast NeoplasmsCarcinoma, Ovarian EpithelialMeningeal CarcinomatosisOvarian NeoplasmsPeritoneal NeoplasmsSmall Cell Lung CarcinomaStomach NeoplasmsSequenzAC (DOXO60/CYCL600), Mamma-Ca, adj. (PID394) -|- PACL175, Mamma-Ca, adj. (PID396)AC (DOXO60/CYCL600), Mamma-Ca, adj. (PID599) -|- DOCE100, adj. (PID395)AC (DOXO60/CYCL600), Mamma-Ca, adj. (PID599) -|- PACL80, adj. (PID581)AC (DOXO60/CYCL600), Mamma-Ca, adj. (PID599) -|- PACL80/TRAS4, adj., Z1 (PID932) -|- Z2-12 (PID933) -|- TRAS6, adj. (PID1474)AC (DOXO60/CYCL600), Mamma-Ca, adj., dd (PID402) -|- PACL175, adj., dd (PID403)ALTERNATIVE: TRAS8/LAPA1000/LETZ2,5, Mamma-Ca, Z1 (PID1768) -|- TRAS6/LAPA1000/LETZ2,5, Mamma-Ca, Z2+ (PID1769)APHINITY: FEC (FU500/EPIR100/CYCL500), Mamma-Ca, adj. (PID388) oder AC (DOXO60/CYCL600), adj. (PID599) oder AC (DOXO60/CYCL600), adj., dd (PID402) -|- PERT840/TRAS8/DOCE75, Mamma-Ca adj., Z1 (PID1165) -|- Z2-4 (PID1166) -|- Z5-18 (PID680)APHINITY: FEC (FU500/EPIR100/CYCL500), Mamma-Ca, adj. (PID388) oder AC (DOXO60/CYCL600), adj. (PID599) oder AC (DOXO60/CYCL600), adj., dd (PID402) -|- PERT840/TRAS8/PACL80, Mamma-Ca, adj., Z1 (PID1167) -|- Z2-4 (PID1168) -|- Z5-18 (PID680)ATRACTIB: ATEZ840/BEVA10/PACL90, Mamma-Ca (PID3050) -|- ATEZ840/BEVA10, Erh. (PID3051)CALGB 40302: LAPA1500/FLVS(500/250), Mamma-Ca, Z1 (PID1770) -|- LAPA1500/FLVS250, Mamma-Ca, Z2+ (PID1771)CALGB 40603: PACL80/CRBP6, Mamma-Ca (PID1552) -|- AC (DOXO60/CYCL600), adj., dd (PID402)CAPItello-291: CAPI400/FLVS500/GOSE3,6, Mamma-Ca, Z1 (PID2609) -|- Z2+ (PID2610)CBCSG010: CAPE1000/DOCE75, Mamma-Ca, adj. (PID1643) -|- CAPE1000/EPIR75/CYCL500, adj. (PID1644)CLEOPATRA: PERT840/TRAS8/DOCE75, Mamma-Ca, Z1 (PID361) -|- PERT420/TRAS6/DOCE75, Z2+ (PID364)CREATE-X: CAPE1250, Mamma-Ca, adj. (PID1370)DESTINY-Breast09: TRASDE5,4/PERT840, Mamma-Ca, Z1 (PID3001) -|- TRASDE5,4/PERT420, Z2+ (PID3002)DESTINY-Breast11: TRASDE5,4, Mamma-Ca, neoadj., Z1-4 (PID3057) -|- PERT840/TRAS6/PACL80 Z5 (PID3058) -|- Z6-8 (PID3059)EC (EPIR90/CYCL600), Mamma-Ca, adj. (PID579) -|- DOCE100, adj. (PID395)EC (EPIR90/CYCL600), Mamma-Ca, adj. (PID579) -|- PACL80, Mamma-Ca, adj. (PID581)EC (EPIR90/CYCL600), Mamma-Ca, adj., dd (PID2702) -|- PACL80, adj. (PID581)EC (EPIR90/CYCL600), Mamma-Ca, adj., dd (PID2702) -|- PACL175, adj., dd (PID403)EC (EPIR90/CYCL600), Mamma-Ca, neoadj. (PID404) -|- DOCE100, neoadj. (PID405)eLEcTRA: TRAS8/LETR2,5, Mamma-Ca, Z1 (PID764) -|- TRAS6/LETR2,5, Mamma-Ca, Z2+ (PID765)EMERALD: PERT840/TRAS8/ERIB1,23, Mamma-Ca, Z1 (PID2870) -|- PERT420/TRAS6/ERIB1,23, Z2+ (PID2871)EPIR90, Mamma-Ca, adj., dd (PID86) -|- PACL175, adj., dd (PID403) -|- CYCL600, adj., dd (PID1143)EPIR150, Mamma-Ca, adj., dd (PID399) -|- PACL225, adj., dd (PID400) -|- CYCL2000, adj., dd (PID401)EVER10/FLVS500, Mamma Ca, Z1 (PID1875) -|- Z2+ (PID1876)FEC-DOC: FEC (FU500/EPIR100/CYCL500), Mamma-Ca, adj. (PID388) -|- DOCE100, adj., Var. 1 (PID389)FeDeriCa: AC (DOXO60/CYCL600), Mamma-Ca, adj. (PID599) -|- Z1 (PID1751) -|- Z2-4 (PID1752) -|- Z5-18 (PID1755)FeDeriCa: AC (DOXO60/CYCL600), Mamma-Ca, adj., dd (PID402) -|- Z1 (PID1753) -|- Z2-4 (PID1754) -|- Z5-18 (PID1755)GBG 69-GeparSepto: NPAC125, Mamma-Ca, neoadj. (PID1354) -|- EC (EPIR90/CYCL600), neoadj. (PID404)GBG 69-GeparSepto: PERT840/TRAS8/NPAC125, Mamma-Ca, neoadj., Z1 (PID1355) -|- Z2-4 (PID1356) -|- Z5-8 (PID1410) -|- PERT420/TRAS6, adj. (PID1350)GBG 69-GeparSepto: PERT840/TRAS8/PAC80, Mamma-Ca, neoadj., Z1 (PID2431) -|- Z2-4 (PID2432) -|- Z5-8 (PID1410) -|- PERT420/TRAS6, adj.GEMC1000/CRBP4/TRAS8, Mamma-Ca, Z1 (PID413) -|- GEMC1000/CRBP4/TRAS6, Mamma-Ca, Z2+ (PID414)HER2CLIMB: TUCA300/CAPE1000/TRAS8, Mamma-Ca, Z1 (PID1761) -|- TUCA300/CAPE1000/TRAS6, Z2+ (PID1762)HERNATA: TRAS8/DOCE100, Mamma-Ca, Z1 (PID416) -|- TRAS6/DOCE100, Mamma-Ca, Z2+ (PID417)HERNATA: TRAS8/VINO30, Mamma-Ca, Z1 (PID418) -|- TRAS6/VINO30, Mamma-Ca, Z2+ (PID419)IMpassion031: Atezolizumab 840 / Nab-Paclitaxel 125, Mammakarzinom, neoadjuvant, Z1-3 (PID2423) -|- Atezolizumab 840 / Doxorubicin 60 / Cyclophosphamid 600, Z4-5 (PID2424) -|- ATEZ1200, adj. (PID2425)INAVO120: INAV9/PALB125/FLVS500, Mamma-Ca, Z1 (PID2804) -|- INAV9/PALB125/FLVS500, Z2+ (PID2805)Intergroup Trial C9741 (Arm II): DOXO60, Mamma-Ca, adj., dd (PID1141) -|- PACL175, adj., dd (PID403), -|- CYCL600, adj., dd (PID1143)KEYNOTE-355: PEMB200/CRBP2/GEMC1000, Mamma-Ca (PID1933) -|- PEMB200, Erh. (PID1931)KEYNOTE-355: PEMB200/NPAC100, Mamma-Ca (PID1930) -|- PEMB200, Erh. (PID1931)KEYNOTE-355: PEMB200/PACL90, Mamma-Ca (PID1932) -|- PEMB200, Erh. (PID1931)KEYNOTE-522: PEMB200/PACL80/CRBP1,5, Mamma-Ca, neoadj., Z1-4 (PID2717) -|- Z5-8 (PID1465) oder oder Z5-8 (PID1466) -|- Z9-17 (PID1868)KEYNOTE-522: PEMB200/PACL80/CRBP5, Mamma-Ca, neoadj., Z1-4 (PID1464) -|- Z5-8 (PID1465) oder Z5-8 (PID1466) -|- Z9-17 (PID1868)MONARCH 2: ABEM150/FLVS500, Mamma Ca, Z1 (PID1408) -|- ABEM150/FLVS500, Mamma Ca, Z2+ (PID1409)monarchE: ABEM150/ANAS1, Mamma-Ca, adj. (PID1785) -|- ANAS1, adj. (PID1581)monarchE: ABEM150/LETR2,5, Mamma-Ca, adj. (PID1786) -|- LETR2,5, adj. (PID1580)monarcHER: TRAS8/ABEM150/FLVS500, Mamma Ca, Z1 (PID1601) -|- TRAS6/ABEM150/FLVS500, Z2+ (PID1602)MutHER: NERA240/FLVS500, Mamma-Ca, Z1 (PID2713) -|- NERA240/FLVS500, Z2+ (PID2714)Neoadjuvant WSG-TP-II (Letrozol)Neoadjuvant WSG-TP-II (Paclitaxel)Neoadjuvant WSG-TP-II (Tamoxifen) -|- PERT840/TRAS8/TMXF20, Mamma-Ca, adj., Z1 (PID2450)NeoSphere Arm B: PERT840/TRAS8/DOCE75, Mamma-Ca, neoadj., Z1 (PID589) -|- Z2-4 (PID750) -|- FEC adj. (PID759) -|- TRAS6 adj. (PID1474)NPAC100/CYCL600/TRAS8, Mamma-Ca, adj. Z1 (PID409) -|- NPAC100/CYCL600/TRAS6, adj. Z2+ (PID410)NPAC125/TRAS(4/2), Mamma-Ca, Z1 (PID427) -|- NPAC125/TRAS2, Z2+ (PID428)PACL80/TRAS4, Mamma-Ca, adj., Z1 (PID932) -|- Z2-12 (PID933) -|- TRAS6, adj. (PID1474)PALOMA3: PALB125/FLVS500, Mamma-Ca, Z1 (PID607) -|- PALB125/FLVS500, Mamma-Ca, Z2+ (PID822)PATINAPERT840, Mamma-Ca, Z1 (PID2607) -|- PERT420, Z2+ (PID2608)PERTAIN: PERT840/TRAS8/ANAS1, Mamma-Ca, Z1 (PID1498) -|- PERT420/TRAS6/ANAS1, Z2+ (PID1500)PERTAIN: PERT840/TRAS8/LETR2,5, Mamma-Ca, Z1 (PID1496) -|- PERT420/TRAS6/LETR2,5, Z2+ (PID1497)RJBC 1501: EC (EPIR90/CYCL600), Mamma-Ca, adj. (PID579) -|- PACL80/CRBP2 (PID3099) oder DOCE75/CRBP5 (PID3100)SAPPHIRE: PERT1200/TRAS600/NPAC125, Mamma-Ca, Z1 (PID1756) -|- Z2+ (PID1757) -|- Erh. (PID1760)SAPPHIRE: PERT1200/TRAS600/PACL80, Mamma-Ca, Z1 (PID1758) -|- Z2+ (PID1759) -|- Erh. (PID1760)SOLAR-1: ALPE300/FLVS500, Mamma-Ca, Z1 (PID1620) -|- ALPE300/FLVS500, Mamma-Ca, Z2+ (PID1621)SWOG S0221: AC (DOXO60/CYCL600), Mamma-Ca, adj., dd, Var. 1 (PID478) -|- PACL80, adj. (PID581)SWOG S0221: AC (DOXO60/CYCL600), Mamma-Ca, adj., dd, Var. 1 (PID478) -|- PACL175, adj., dd, Var. 1 (PID479)TAnDEM: TRAS(4/2)/ANAS1, Mamma-Ca, Z1 (PID755) -|- TRAS2/ANAS1, Mamma-Ca, Z2+ (PID756)TCH (DOCE75/CRBP6/TRAS(4/2)), Mamma-Ca, adj., Z1 (PID411) -|- Z2+ (PID412) -|- TRAS6 adj. (PID1474)TCH (DOCE75/CRBP6/TRAS8), Mamma-Ca, neoadj., Z1 (PID655) -|- Z2+ (PID654) -|- TRAS8, adj., Z1 (PID1687) -|- TRAS6, adj. (PID1474)TRAIN-2: PERT840/TRAS8/PACL80/CRPB6, Mamma-Ca, neoadj., Z1 (PID2121) -|- PERT420/TRAS6/PACL80/CRPB6, Z2-9 (PID2122)TRAS(4/2)/DOCE75/CYCL600, Mamma-Ca, adj., Z1 (PID2721) -|- TRAS2/DOCE75/CYCL600, Z2+ (PID2722) -|- TRAS6 (PID1474)TRAS8, Mamma-Ca, adj., Z1, Var. 1 (PID1687) -|- TRAS6, adj., Z2+, Var. 1 (PID1688)TRAS8, Mamma-Ca, Z1 (PID761) -|- TRAS6, Z2+ (PID760)TRAS80, Meningeosis neoplastica, Z1 (PID2526) -|- Z2 (PID2527) -|- Z3+ (PID2542)TRYPHAENA Arm A: FEC (FU500/EPIR90/CYCL600)/TRAS8/PERT840, Mamma-Ca, neoadj., Z1 (PID1467) -|- Z2-3 (PID1468) -|- Z4-6 (PID750) -|- TRAS6, adj. (PID1474)TRYPHAENA Arm B: FEC (FU500/EPIR90/CYCL600), Mamma-Ca, neoadj., Z1-3 (PID1357) -|- Z4 (PID589) -|- Z5-6 (PID750) -|- TRAS6, adj. (PID1474)TRYPHAENA Arm C: PERT840/TRAS8/DOCE75/CRBP6, Mamma-Ca, neoadj., Z1 (PID1469) -|- Z2-6 (PID1470) -|- TRAS6, adj. (PID1474)VELVET: PERT840/TRAS8/VINO25, Mamma-Ca, Z1 (PID2711) -|- PERT420/TRAS6/VINO30, Z2+ (PID2712)VINO25/CAPE1000, Mamma-Ca (PID1692) -|- CAPE1000 Erh. (PID1693)VINO60/CAPE1000, Mamma-Ca, Z1 (PID942) -|- VINO80/CAPE1000, Z2+ (PID943)ChemotherapieChemo-SubstanzAbemaciclibAlpelisibAnastrozolAtezolizumabAvelumabBevacizumabCapecitabinCapivasertibCarboplatinCatumaxomabCisplatinCyclophosphamidDatopotamab DeruxtecanDocetaxelDoxorubicinDoxorubicin liposomalDoxorubicin pegyliert liposomalElacestrantEpirubicinEribulinEverolimusExemestanFluorouracilFulvestrantGemcitabinGoserelinHydrocortisonInavolisibLapatinibLetrozolLeuprorelinMargetuximabMethotrexatMitoxantronNab-PaclitaxelNaCl 0,9%NeratinibOlaparibPaclitaxelPalbociclibPembrolizumabPertuzumabRibociclibSacituzumab GovitecanTalazoparibTamoxifenThiotepaTopotecanTrastuzumabTrastuzumab DeruxtecanTrastuzumab EmtansinTrofosfamidTucatinibVinorelbinChemo-SubstanzAbemaciclibAlpelisibAnastrozolAtezolizumabAvelumabBevacizumabCapecitabinCapivasertibCarboplatinCatumaxomabCisplatinCyclophosphamidDatopotamab DeruxtecanDocetaxelDoxorubicinDoxorubicin liposomalDoxorubicin pegyliert liposomalElacestrantEpirubicinEribulinEverolimusExemestanFluorouracilFulvestrantGemcitabinGoserelinHydrocortisonInavolisibLapatinibLetrozolLeuprorelinMargetuximabMethotrexatMitoxantronNab-PaclitaxelNaCl 0,9%NeratinibOlaparibPaclitaxelPalbociclibPembrolizumabPertuzumabRibociclibSacituzumab GovitecanTalazoparibTamoxifenThiotepaTopotecanTrastuzumabTrastuzumab DeruxtecanTrastuzumab EmtansinTrofosfamidTucatinibVinorelbinChemo-SubstanzAbemaciclibAlpelisibAnastrozolAtezolizumabAvelumabBevacizumabCapecitabinCapivasertibCarboplatinCatumaxomabCisplatinCyclophosphamidDatopotamab DeruxtecanDocetaxelDoxorubicinDoxorubicin liposomalDoxorubicin pegyliert liposomalElacestrantEpirubicinEribulinEverolimusExemestanFluorouracilFulvestrantGemcitabinGoserelinHydrocortisonInavolisibLapatinibLetrozolLeuprorelinMargetuximabMethotrexatMitoxantronNab-PaclitaxelNaCl 0,9%NeratinibOlaparibPaclitaxelPalbociclibPembrolizumabPertuzumabRibociclibSacituzumab GovitecanTalazoparibTamoxifenThiotepaTopotecanTrastuzumabTrastuzumab DeruxtecanTrastuzumab EmtansinTrofosfamidTucatinibVinorelbinChemo-SubstanzAbemaciclibAlpelisibAnastrozolAtezolizumabAvelumabBevacizumabCapecitabinCapivasertibCarboplatinCatumaxomabCisplatinCyclophosphamidDatopotamab DeruxtecanDocetaxelDoxorubicinDoxorubicin liposomalDoxorubicin pegyliert liposomalElacestrantEpirubicinEribulinEverolimusExemestanFluorouracilFulvestrantGemcitabinGoserelinHydrocortisonInavolisibLapatinibLetrozolLeuprorelinMargetuximabMethotrexatMitoxantronNab-PaclitaxelNaCl 0,9%NeratinibOlaparibPaclitaxelPalbociclibPembrolizumabPertuzumabRibociclibSacituzumab GovitecanTalazoparibTamoxifenThiotepaTopotecanTrastuzumabTrastuzumab DeruxtecanTrastuzumab EmtansinTrofosfamidTucatinibVinorelbinAnzahl Chemo12345 StrahlentherapieSupportivtherapieSupportiv-SubstanzCimetidinCiprofloxacinClodronsäureDexamethasonDimetindenFilgrastimFosaprepitantGranisetronHyaluronsäureJonosterilKaliumchloridLoperamidMagnesiumMagnesiumsulfatMesnaNaCl 0,9%ParacetamolPegfilgrastimPrednisolonPyridoxinZoledronsäureSupportiv-SubstanzCimetidinCiprofloxacinClodronsäureDexamethasonDimetindenFilgrastimFosaprepitantGranisetronHyaluronsäureJonosterilKaliumchloridLoperamidMagnesiumMagnesiumsulfatMesnaNaCl 0,9%ParacetamolPegfilgrastimPrednisolonPyridoxinZoledronsäureSupportiv-SubstanzCimetidinCiprofloxacinClodronsäureDexamethasonDimetindenFilgrastimFosaprepitantGranisetronHyaluronsäureJonosterilKaliumchloridLoperamidMagnesiumMagnesiumsulfatMesnaNaCl 0,9%ParacetamolPegfilgrastimPrednisolonPyridoxinZoledronsäureSupportiv-SubstanzCimetidinCiprofloxacinClodronsäureDexamethasonDimetindenFilgrastimFosaprepitantGranisetronHyaluronsäureJonosterilKaliumchloridLoperamidMagnesiumMagnesiumsulfatMesnaNaCl 0,9%ParacetamolPegfilgrastimPrednisolonPyridoxinZoledronsäureAnzahl Supportiv1234567ProtokollklassifikationTherapieklassifikationaktueller StandardalternativstudienanalogStudienprotokoll, aktuellIntensitätdosisdichtdosisintensiviertNiedrig-DosisStandard-DosisTherapieindikationDrittlinieErstliniemehrere möglichRezidiv-TherapieZweitlinieTherapiephaseadjuvantErhaltungInduktionmehrere möglichneoadjuvantneoadjuvant / adjuvantpost-neoadjuvantTherapieintentionKrankheitskontrollekurativpalliativsupportivRisikenabdominelle SchmerzenAbgeschlagenheitAllergische ReaktionAlopezieAnorexieAnämie Hb unter 8g/dlAnämie Hb unter 10g/dlArachnoiditisArthalgienAsthenieBenommenheitColitisCOVID-19 InfektionDepressionDiarrhoeDyspnoeEmetogenitätEmetogenität (ASCO)Emetogenität (MASCC/ESMO)ErbrechenErhöhung AminotransferasenExanthem, akneiformfebrile Neutropeniegastrointestinale Toxizitätgrippeartige SymptomeHand-Fuß-SyndromHautausschlagHepatotoxizitätHerzinsuffizienzHyperbilirubinämieHyperglykämieHypertensionHyperthyreoseHypertriglyzeridämieHypokaliämieHypokalzämieHypomagnesiämieHyponatriämieHypophosphatämieHypothyreoseHämaturieHämorrhagieInfektion der oberen AtemwegeInfektionenInfusionsreaktionKardiotoxizitätKeratopathieKieferosteonekroseKnochenschmerzenKolitisKonjunktivitisKopfschmerzenKrampfanfälleLeukopenieLungenfibroseLymphopenieMukositisMyalgienNagelveränderungenNauseaNeuropathieNeurotoxizitätNeutropenieObstipationÖdemeorale MukositisOsteopeniePneumoniePneumonitisPruritusPyrexieSchmerzenSehstörungenTachykardieThromboembolisches EreignisThrombozytopenie unter 50 000/µlTrockenes AugeTränenträufeln nur StudienprotokollePublikationAutorAdams SAddeo RAl-Batran SAlbain KSAndersson MAndre FBardia ABardia A / Cortes JBaselga JBastholt LBatist GBayraktar SBidard FCBudd GTBurstein HJChan AChan SChen XCinieri SCitron MLColeman RColleoni MCoombes RCCortes JCortés JDecker TDenise YardleyDiel IDi Leo ADirix LEarly Breast Cancer Trialists Collaborative Group (EBCTCG)Finn RGasparini G Geyer CEGianni LGianni L / Schneeweiss AGion MGluz OGnant MGoetz MGradishar WJGroves MHamilton EHarbeck NHarvey VHeidemann EHeiss MMHochster HHortobagyi GHuober JHu XCIm SAIsakoff SJJackisch CJ CarmichaelJohnston SRDJones EJones RLJones SEKaufman BKorblum NKotake MKrop IEKumthekar PLang ILangley RELi JLitton JLiu YLoesch DLoibl SLück HJMa CXMaisch BMalinovszky K Martin MMartinoni A Masuda NMehta RSMinckwitz GMirtsching BMittendorf EModi SMoebus VMontagna EMross KMurthy RKMuss HBNabholtz JMO'Shaughnessy JOberkampf FPark YHPerez EAPerez EA Perrone FPiccart MRimawi MRivera ERobson MRoché HRugo HSSaura CSawaki MSchmid PSchneeweiss ASeidman ADSharma PSikov WMSlamon DSledge GWSmith ISparano JAStemmer HJStockler MRTan ARTolaney STolaney SMTurner NCTutt ATutt ANJUntch Mvan Ramshorst MSvan Rossum AGJVerma Svon Minckwitz GWang JWang XWoodward NYamashita TYardley DYardley DAZhang JErkrankungFortgeschrittenes Mamma-Ca, Erstliniefortgeschrittenes Mamma-Ca, HR+, HER-2-, ECOG 0-1fortgeschrittenes Mamma-Ca, ungeeignet für intensivere Chemotherapiefortgeschrittenes Mamma-Ca, Zweitlinie, ECOG 0-2fortgeschrittenes Mammakarzinom, HR+, HER2-, Erstlinie, ECOG 0-1fortgeschrittenes metastasiertes MammakarzinomFortgeschrittenes oder metastasiertes Mammakarzinom, HR+, Her2-, nach endokriner Vortherapie, ECOG 0-1fortgeschrittenes oder rezidiviertes Mammakarzinom, HR+, Her2neu+, ECOG 0-1, mind. 2 anti-Her2-Vortherapien im palliativen SettingHER2+ Brustkrebs, adjuvant oder neoadjuvant, ECOG 0-2HER2+ Brustkrebs, neoadjuvant, ECOG 0-2HER2+ Mamma-Ca, adjuvante Erhaltung nach neoadjuvanter ChemotherapieHER2+ Mamma-Ca, adjuvante Therapie, 70-80 J.HER2+ und Hormonrezeptor +, metastasiertes Mamma-Ca, postmenopausalm, ECOG 0-1HER2+ und HR+, lokal fortgeschrittenes oder metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1HER2+ und HR+, lokal fortgeschrittenes oder metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1HER2+ und HR+, metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1Hormon Rezeptor +, HER2 -, fortgeschrittenes oder wiederkerhrendes Mammakarzinom während vorangegangengener endokriner Therapie, ECOG 0-1Hormon Rezeptor +, HER2 -, fortgeschrittenes oder wiederkerhrendes Mammakarzinom während vorangegangengener endokriner Therapie.Hormon Rezeptor +, HER2 -, lokal fortgeschrittenes Mammakarzinom, Erstlinie, ECOG 0-2Leptomeningeale Metastasen beim Mamma-Ca, HER2+, ECOG 0-3Leptomeningeale Metastasen beim Mamma-Ca, HER2+, Karnofsky >50lokal fortgeschrittenes, nicht resezierbares oder metastasierendes Mamma-Ca, triple neg., Erstlinie, ECOG 0-1Lokal fortgeschrittenes, oder metastasiertes Mamma-Ca, tripel-negativ, metastasiert, Drittlinie und Erstlinie ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Mamma-Ca, Her2+, mindestens 2 gegen HER2 gerichtete Behandlungsschemata, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Mamma-Ca, tripel negativ, PD-L1+ (CPS ≥10), ECOG 0-1lokal fortgeschrittenes oder metastasiertes Mamma-Ca, Zweitlinie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Mammakarzinom, BRCA-Mutation, Her2-, ECOG 0-2, bis 3 vorausgegangene ChemotherapielinienLokal fortgeschrittenes oder metastasiertes Mammakarzinom, HR+, HER2+, nach vorangegangener endokriner Therapie.Lokal fortgeschrittenes oder metastasiertes Mammakarzinom, HR+, HER2+, postmenopausal, ECOG 0-1Maligner Perikarderguss, hämodynamisch relevantMaligner Perikarderguss beim Mamma-Ca, hämodynamisch relevantMamma-Ca, adjuvantMamma-Ca, adjuvant, <70 J., ECOG 0-1Mamma-Ca, adjuvant, ECOG 0-1, Beginn innerhalb von 42 Tagen nach der OPMamma-Ca, adjuvant, ECOG 0-1, Beginn innerhalb von 42 Tagen nach der OPMamma-Ca, HER2+, adjuvantMamma-Ca, HER2+, ECOG 0-2Mamma-Ca, HER2+, nach neoadjuvanter ChemotherapieMamma-Ca, high risk, Stadium I-III, adjuvantMamma-Ca, high risk, Stadium I-III oder 0-3 befallene Lymphknoten, adjuvantMamma-Ca, LK-positiv, adjuvantMamma-Ca, met. oder fortgeschr., ER+, postmenopausalMamma-Ca, metastasiert, tripel-negativ, ECOG 0-1Mamma-Ca, metastasiert oder hohes Rezidivrisiko, 65-79 Jahre, adjuvant, ECOG 0-1Mamma-Ca, metastasiert oder rezidiviert, prämenopausal, HR+, HER2-, ECOG 0-2Mamma-Ca, N+Mamma-Ca, N-positiv, adjuvantMamma-Ca, nach neoadjuvanter Chemotherapie, HER2-negativ, ECOG 0-1Mamma-Ca, neoadjuvantMamma-Ca, operabel, Stadium II–IIIC, Her2+, ECOG 0-1Mamma-Ca, Stadium I-IV, adjuvantMamma-Ca, Stadium Ib-IIIc, nach neoadjuvanter Chemotherapie, tripel-negativMamma-Ca, Stadium II oder III, HR+, HER2-, ECOG 0-1Mamma-Ca, tripel-negativ, ECOG 0-1Mamma-Ca, tripel-negativ, Stadium II/III, neoadjuvante TherapieMamma-Ca, tripel neg., operabel, Erstlinie, ECOG 0-1Mamma-Ca Stadium I und II, HR+, adjuvant, prämenopausalMammakarzinom, adjuvant, 65 Jahre oder älter, ECOG 0-2Mammakarzinom, BRCA-Mutation, HER2-, ECOG 0-1Mammakarzinom, BRCA-Mutation, HER2-, nach neoadjuvanter oder adjuvanter taxan- und/oder anthrazyklinhaltiger Chemotherapie, ECOG 0-1Mammakarzinom, cT1c-T4a-c, cN0/N+, cM0, HER2+ (IHC/FISH), ECOG 0-1Mammakarzinom, Her2 amplifiziert, adjuvantMammakarzinom, Her2 negativ, metastasiert, nach mind. 2 Vortherapien, ECOG 0-1Mammakarzinom, Her2 pos., Drittlinie oder höher, ECOG 0-1Mammakarzinom, HER2+, ECOG 0-1Mammakarzinom, HER2+, Frühstadium, neoadjuvantMammakarzinom, HER2+, T1-4, N0-3, M0, residuelles Karzinom nach neoadjuvanter Therapie (postneoadjuvant), ECOG 0-1Mammakarzinom, HER2+ ECOG 0-2Mammakarzinom, HER2+ und HR+, postmenopausal, ECOG 0-1Mammakarzinom, HER2- (0 oder 1+ in der IHC), HER2 mutiert, ECOG 0-2Mammakarzinom, HR+, HER2-, Hochrisiko, adjuvantMammakarzinom, HR+, Her2-, PIK3CA+, nach vorangegangengener adjuvanter endokriner Therapie oder primär metastasiert ohne vorangegangene endokrine TherapieMammakarzinom, HR+, nodalpositiv (Stadium IIA-IIIC), ECOG 0-1Mammakarzinom, HR+, Stadium I-IIICMammakarzinom, lokal fortgeschritten oder metastasiert, ECOG 0-2Mammakarzinom, lokal fortgeschritten oder metastasiert, Her2+, DFI zwischen letzter (neo)adjuvanten CHT oder HER2-gezielte Therapie > 6 Monate, ECOG 0-1Mammakarzinom, lokal fortgeschritten oder metastasiert, Her2+: nach vorheriger Therapie mit Trastuzumab Emtansin oder HR+, nach endokriner Therapie, ECOG 0-1Mammakarzinom, lokal fortgeschritten oder metastasiert, HR+, Her2-, PIK3CA, AKT1 oder PTEN mutiert, nach vorheriger endokriner TherapieMammakarzinom, lokal fortgeschritten oder metastasiert, HR+, Her2-, PIK3CA mutiert, nach vorheriger endokriner TherapieMammakarzinom, lokal fortgeschritten oder metastasiert, mindestens 1 Vortherapie, inkl. adjuvante Behandlung, ECOG 0-2Mammakarzinom, metastasiert, Karnofsky-Score über 50, ZweitlinientherapieMammakarzinom, metastasiert, nach anthrazyklinhaltiger Chemotherapie, ECOG 0-1Mammakarzinom, postmenopausal, HR+ oder unbekannt, nach adjuvanter 2-3-jähriger Therapie mit TamoxifenMammakarzinom, Stadium I-III, HER2+, Trastuzumabtherapie bis zu 2 Jahren, ECOG 0-1Mammakarzinom, tripel-negativ, 18-69 J., adjuvantMammakarzinom, tripel-negativ, neoadjuvant, Erstlinie, ECOG 0-1Mammakarzinom, tripel negativ, ECOG 0-1Mammakarzinom, tripel negativ, ECOG 0-2Mammakarzinom, tripel negativ, Stadium I-IIIMammakarzinom, tripel negativ, ZweitlinieMammakarzinom, triple negativ, metastasiert oder rezidiviert, inoperabel, ECOG 0-1Mammakarzinom, Östrogenrezeptor+, HER2-, ESR1-Mutation , Drittlinie nach CDK4/6-Inhibitor und Chemotherapie, ECOG 0-1Mammakarzinom adjuvant, HER2+, Tumor < 3 cmMammakarzinom Stadium IIA-IIIB, R0-Resektion, Karnofsky > 80met. Mamma-Ca, 2-5 Vortherapien (Taxan oder Anthracyclin enthaltend) oder 2 oder mehr Vortherapien bzgl. des met. Stadiums, ECOG 0-2met. Mamma-Ca, ECOG 0-2, Erstlinie im met. Stadium, im Falle anthrazyklinhaltiger Vortherapien (neo-/adj.) mehr 12 Monate Intervallmet. Mamma-Ca, Erstlinie im met. Stadium nach vorangeg. neo-/adjuvanter anthrazyklinhaltiger Chemotherapiemet. Mamma-Ca, Erstlinie in met. Stadiummet. Mamma-Ca , Erstlinie in met. Stadiummet. Mamma-Ca, Progress nach mehreren Therapienmet. Mamma-Ca HER2+, Drittlinie mit Trastuzumab, Lapatinib und Taxan in der Vortherapiemet. Mamma-Ca HER2+, Erstliniemet. Mamma-Ca HER2+, Progress nach Behandlung mit Regimen die Anthrazykline, Taxane und Trastuzumab beinhaltetenmet. Mamma-Ca HER2+, Zweitlinie nach Vorbehandlung mit Trastuzumab + Taxanmet. Mamma-Ca HER2negativ, ECOG 0-1, max. eine Vortherapie bzgl. der met. Erkrankungmet. Mamma-Ca HR+/HER2+, postmenopausal, Progress nach Behandlung mit endokriner Therapie oder Trastuzumab/Chemotherapie, ECOG 0-1Metastasiertes, HER2+ Mamma-Ca, ECOG 0-2metastasiertes, HER2+ Mamma-Ca, ECOG 0-2metastasiertes, tripel-negatives Mamma-Ca, PD-L1+, ECOG 0-1Metastasiertes, tripel-negatives Mamma-Ca, PD-L1+, ECOG 0-1metastasiertes, triple-negatives Mamma-Ca, Erstlinie, ECOG 0-1metastasiertes Mamma-Ca, ECOG 0-1, vorbehandeltMetastasiertes Mamma-Ca, ECOG 0-1, vorbehandeltMetastasiertes Mamma-Ca, Erst- bis Viertlinie im met. Stadium, kein Taxan in den pall. Vortherapienmetastasiertes Mamma-Ca, Erst- und ZweitlinientherapieMetastasiertes Mamma-Ca, Erstliniemetastasiertes Mamma-Ca, Erstlinie, ECOG 0-2metastasiertes Mamma-Ca, Erstlinie, ohne anthrazyklinhaltige Vortherapie, ECOG 0-2Metastasiertes Mamma-Ca, Erstlinie in met. Stadium, Patientinnen älter als 70 JahreMetastasiertes Mamma-Ca, Erstlinie in metastasiertem Stadiummetastasiertes Mamma-Ca, Erstlinie in metastasiertem Stadium, ECOG 0-1metastasiertes Mamma-Ca, Erstlinientherapie, ECOG 0-3metastasiertes Mamma-Ca, HER2-, Erstlinie, Karnofsky > 70Metastasiertes Mamma-Ca, HER2-, Erstlinie, Karnofsky > 70Metastasiertes Mamma-Ca, HER2-negativ, ECOG 0-2, ErstlinieMetastasiertes Mamma-Ca, HR+ postmenopausal, ECOG: 0-2metastasiertes Mamma-Ca, Progress nach mehreren TherapienMetastasiertes Mamma-Ca, tripel-negativ, ErstlinieMetastasiertes Mamma-Ca, tripel-negativ, Erstlinie, ECOG 0-1metastasiertes Mamma-Ca, triple-negativMetastasiertes Mamma-Ca der Frau, ECOG 0-2, Erstlinientherapie, keine Herzinsuffizienz NYHA II-IV, kein Myokardinfarkt in den letzten 6 Mo.Metastasiertes Mamma-Ca HER2 negativ, ECOG 0-2, ErstlinieMetastasiertes Mammakarzinom, ECOG 0-2Metastasiertes Mammakarzinom, ECOG 0-2, bis zu 2 VortherapienMetastasiertes Mammakarzinom, Karnofsky-Index über 60%, Drittlinie oder höhermetastasiertes Mammkarzinom, Rezidivtherapie, Karnofsky Status > 70%Metastasiertes oder lokal fortgeschrittenes Mamma-Ca, ERBB2-pos., mind. 2 VortherapienMetastasiertes oder lokal fortgeschrittenes Mamma-Ca, Her2-pos., mind. 2 VortherapienNicht resezierbares oder metastasiertes Mamma-Ca, HR+/HER2-, ECOG 0-1operables, lokal fortgeschrittenes Mamma-Ca, Tumor > 2cm, HER2+, ECOG 0-1operables, lokal fortgeschrittenes oder entzündliches Mamma-Ca, HER-2+, Erstlinie, ECOG 0-1Paclitaxel wöchentlich, Mammakarzinom, adjuvantPeritonealkarzinose, sekundär, EpCAM positiv in malignen Zellen in Aszitespostmenopausale Frauen, fortgeschr. Mamma-Ca, HR+, HER2-, Progress nach Anastrozol oder Letrozolprim. Brustkrebs, 18-65 Jahre, R0-Resektion, HER2+, Karnofsky Status > 80%prim. Brustkrebs, 18-65 Jahre, R0-Resektion, Karnofsky Status > 80%primäres Mamma-Caprimäres Mamma-Ca, adjuvant, HER2+primäres Mamma-Ca, HR+, HER2+, Karnofsky > 80Refraktäre Meningeosis neoplastica, Erstlinie für Meningeosis neoplastica, Karnofsky > 60residuelles invasives, nicht met. Mamma-Ca HER2+, nach neoadjuvanter Vorbehandlung mit Trastuzumab und Taxanrezidivierendes oder metastasiertes Mamma-Ca, postmenopausal, HR+, HER2-, Erstlinie, ECOG 0-1rezidivierendes oder metastasiertes Mamma-Ca, prä- und perimenopausal, HR+, HER2-, ECOG 0-1Rezidiviertes oder metastasiertes Mammakarzinom, ECOG 0-2Rezidiviertes oder metastasiertes Mammakarzinom, Zweitlinie, ECOG 0-2triple-negatives Mamma-Ca neoadjuvant, Erstlinie, Karnofsky Status > 80HerkunftAcademic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK, AZURE InvestigatorsAGO Breast Cancer GroupAlbert Einstein College of Medicine, Bronx, New York, USA, PrE0102 TrialAllegheny General Hospital, Pittsburgh, USABarts Cancer Institute, Queen Mary University of London, IMpassion130 TrialBaylor-Sammons Cancer Center, Dallas, and US Oncology, Houston, USABreast and Gynecologic Cancer Medicine Service, Sloan-Kettering Institute for Cancer Research, New York, USABreast Cancer International Research Group, BCIRG 001 StudieBreast Cancer International Research Group, BCIRG 006 StudieBreast Cancer Now Research Centre, The Institute of Cancer Research, London, the TNT trialBreast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College LondonBreast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia, ExteNETBreast Cancer Unit, Kyoto University Hospital, JapanBreast Center, Department of OB and GYN, LMU University Hospital and CCC Munich, DESTINY-Breast11 trialBreast Center, University of Munich, GermanyBreast Center Kantonsspital St. Gallen, Schweiz, eLEcTRA trialBreast Oncology, Department of Medicine und Robert H. Lurie Comprehensive Cancer Center, Chicago, USABreast Unit, Royal Marsden NHS Trust, London, UKCancer and Leukemia Group B, Intergroup Trial C9741Cancer Research UK, Imperial College London, Hammersmith Hospitals Trust, London, UKCardiology Unit, Milan, ItalyCenter for Oncology Research and Treatment, Dallas, Texas, USAChinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaCleopatra Study Group, CLEOPATRA StudieClinical Trial Centre, University of Sydney, AustraliaClinical Trial Service Unit, Oxford, UK Clinical Trials Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G. Pascale–IRCCS, NapolCologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, GermanyComprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, RJBC 1501 trialDana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA, IMpassion031 TrialDana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA IMpassion031 TrialDana-Farber Cancer Institute, Boston, CALGB 40302Dana-Farber Cancer Institute, Boston, MA, DESTINY-Breast09 trialDana-Farber Cancer Institute, Boston, MA, USA, monarcHER trialDana-Farber Cancer Institute and Harvard Medical School, Boston, MA, ASCENT-04/ KEYNOTE-D19 studyDan L. Duncan Comprehensive Cancer Center, Baylor College ofMedicine, Houston, PERTAIN StudieDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, PERTAIN StudieDavid Geffen School of Medicine at the University of California, Los Angeles, NATALEE trialDepartment of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TexasDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, JapanDepartment of Hematology and Medical Oncology, Deaconess Hospital, Oncological Center of Stuttgart, GermanyDepartment of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyDepartment of Medical Oncology, Dana–Farber Cancer Institute, BostonDepartment of Medical Oncology, Toulouse, Frankreich. FNCLCC PACS 01 StudieDepartment of Medical Oncology, Touluse, Frankreich. FNCLCC PACS 01 StudieDepartment of Medicine,Memorial Sloan Kettering Cancer Center, New York, USADepartment of Neurology at The Feinberg School of Medicine at Northwestern University, USDepartment of Obstetrics and Gynecology, Sana Klinikum Offenbach, HannaHDepartment of Obstetrics and Gynecology, University of Heidelberg, HeidelbergDepartment of Oncology, Auckland Hospital, AucklandDepartment of Oncology, Copenagen, DänemarkDepartment of Oncology, Copenagen, Dänemark, HERNATA StudieDepartment of Oncology, Institut Curie-St Cloud, FranceDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Shanghai Medical College, Fudan University, ChinaDepartment of Solid Tumor Oncology, Taussig Cancer Center, Cleveland, USA SWOG S0221Dipartimento di Oncologia, Napoli, ItalienDivision of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, HoustonDivision of Cancer Medicine, University of Texas M.D. Anderson Cancer CenterDivision of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, USADivision of Medical Oncology, Instituto Europeo di Oncologia, Milan, ItalyDivision of Medical Oncology, Massachusetts General Hospital Cancer Center, ASCENT trial / ASCENT-03 trialDivision of Medical Senology, European Institute of Oncology, Milan, ItalyDuke Cancer Institute, Durham, USAEastern Cooperative Oncology Group, Philadelphia, USEMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigatorsEMILIA Study Group, EMILIA StudieFudan University Shanghai Cancer Center, Shanghai, People's Republic of China, CBCSG010 StudyFudan University Shanghai Cancer Center, Shanghai, People’s Republic of China, CBCSG010 StudyFudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, ChinaGBG Forschung, Neu-Isenburg, APHINITY Steering Committee and InvestigatorsGeparSixto StudieGerman Breast Group, Frankfurt, GermanyGerman Breast Group, GBG Forschungs, Martin-Behaim- Str. 12, Neu-Isenburg, KATHERINEGerman Breast Group, Neu-Isenburg, Germany, DESTINY-Breast05 TrialGunma Prefectural Cancer Center, Takahayashinishi, Ota, Gunma, JapanHelios Klinikum Berlin-Buch, GermanyHelios Klinikum Berlin-Buch, Germany, GeparSeptoImperial Cancer Research Fund Clinical Oncology Unit, Churchill Hospital, Oxford, United KingdomInstitut Curie, Paris and Saint Cloud, France, EMERALD TrialInstitut Gustave Roussy, Villejuif, France, SOLAR-1 StudyInstitut Jules Bordet, Université Libre de Bruxelles, Belgien; BOLERO-2 StudieInternational Breast Cancer Center, Vall d'Hebron Institute of Oncology, Barcelona, Spain, KEYNOTE-355Jewish General Hospital, McGill University, Montreal, Quebec, CanadaKanagawa Cancer Center, Kanagawa, Japan, EMERALD TrialKEYNOTE-522 InvestigatorsKlinik für Internistische Onkologie, Freiburg, DeutschlandKlinikum Frankfurt Höchst, Academic Hospital of the Goethe University Frankfurt, Frankfurt, GAIN trialKrankenhaus Nordwest und German Breast Group, FrankfurtLevine Cancer Institute, Atrium Health, Charlotte, NC, USA, FeDeriCa trialLoyola University Chicago Stritch School of Medicine, Maywood, USALudwig-Maximilians University of Munich, Campus Grosshadern, Munich, GermanyM.D. Anderson Cancer Center, Houston, USA, HER2CLIMB trialM.D. Anderson Cancer Center, University of Texas, Houston, EMBRACA StudieMassachusetts General Hospital Cancer CenterMassachusetts General Hospital Cancer Center, Boston, USAMater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Queensland, Australia, SAPPHIREMater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Queensland, Australia, SAPPHIRE trialMayo Clinic, Rochester, MN, Monarch 3 trialMcKesson Specialty Health, The Woodlands, TX, USAMedical Oncology and Breast Unit, European Institute of Oncology (IRCCS), Milan,Italy, NorCap-CA223 TrialMedical University of Vienna, ABCSG-12 trialMemorial Sloan Kettering Cancer Center, New York, OlympiAD TrialMemorial Sloan Kettering Cancer Center, New York, USA, DESTINY-Breast01 trial / DESTINY-Breast06 trialMiriam Hospital and Alpert Medical School of Brown University, Providence, USA, CALGB 40603 (Alliance)National Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, AustraliaNetherlands Cancer Institute, Amsterdam, Netherlands, TRAIN-2 trialNetherlands Cancer Institute, Amsterdam, The Netherlands, The Triple-B studyNew York University Medical Center, New York, New York, USANorthwestern University, Breast Oncology, Division of Hematology/Oncology, Department of Medicine, Chicago, USAOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trialOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trial, sowie National Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trial sowie National Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaOnkologie Ravensburg, Elisabethenstraße 19, 88212, Ravensburg, Germany, VicTORia trialPeking University Cancer Hospital and Institute, Beijing, People's Republic of ChinaPerlmutter Cancer Center, New York University School of Medicine, KEYNOTE-086Research Institute and Tennessee Oncology PLLC, Medical Oncology, Nashville, USA, tnAcity trialRoyal Marsden Hospital, Institute of Cancer Research, London, CAPItello-291 trialRoyal Marsden Hospital, London, United KingdomRoyal Marsden Hospital and Institute of Cancer Research, London, INAVO120 trialRoyal Marsden Hospital and Institute of Cancer Research, London, PALOMA-3Royal Marsden NHS Foundation Trust, London, United Kingdom, monarchE trialSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, KCSG-BR15-10Sandro Pitigliani Medical Oncology Unit, Hospital Prato, ItalienSarah Cannon Research Institute, Nashville, USASarah Connor Reearch Inst. Nashville TN USASint Augustinus-University of Antwerp, Antwerp, Belgium, JAVELIN studySOLTI Breast Cancer Cooperative Group, Barcelona, Spain, NALA TrialSouth West Wales Cancer Institute, University of Wales, Wales, UK, TEXAS StudieSpanish Breast Cancer Research Group, GEICAM trialSt. Bortolo Hospital, Vicenza, ItalyStanford University, School of Medicine, MONARCH 2Sun Yatsen University Cancer Center, the State Key Laboratory of Oncology in South China, SYSUCC-001 trialTAnDEM studyTaxotere EXperience with Anthracyclines Study; TEXAS StudieTh3resa Studiengruppe, TH3RESA StudieThe AGO Breast and the German Breast Group GAIN-2 StudienprotokollThe Central European Cooperative Oncology Group, TURANDOT StudieThe Eastern Cooperative Oncology Group, Southwest Oncology Group, Cancer and Leukemia Group, Noth Central Cancer Treatment GroupThe German Breast Group, Arbeitsgemeinschaft Gynäkologische Onkologie Breast Group InvestigatorsThe Medical Research Council Clinical Trials UnitThe Myocet Study GroupThe Royal Marsden Hospital and Institute of Cancer Research, Surrey, United KingdomThe Royal Marsden NHS Foundation Trust, London, United Kingdom, ALTERNATIVE trialThe TAX 306 Study GroupTROPION-Breast01 InvestigatorsU.S. Oncology, Inc, Houston, TXUCLA Medical Center, Santa Monica, CA, MONALEESA-3University Hospital Ramon y Cajal, Madrid, Spain, ATRACTIB trialUniversity of California Irvine Medical CenterUniversity of California Los Angeles, Los Angeles, CA, USA, PALOMA-1/TRIO-18University of California San Francisco Helen Diller Family Comprehensive Cancer Center, SOPHIA TrialUniversity of Kansas Medical Center, Westwood, KansasUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA, CALGB 49907 TrialUniversity of Texas M.D. Anderson Cancer Center, Houston, MONALEESA-7University of Texas M. D. Anderson Cancer Center, Houston, TXUS Medical Affairs, Genentech, Inc., South San Francisco, USA, VELVET trialUS Oncology Research, Texas Oncology, Dallas, USAVall d’Hebron, University Hospital, Barcelona; Hospital Arnau de Vilanova, Lleida, SpainWashington University School of Medicine, St. Louis, Missouri, MutHER StudyWest German Study Group, Moenchengladbach, Deutschland, WSG-ADAPT-TNWest German Study Group, Mönchengladbach, Germany, The Neoadjuvant WSG-TP-II Randomized Clinical TrialProtokolle in Überarbeitung 271 Protokolle gefundenAbemaciclib 150 / Anastrozol 1, Mammakarzinom (PID567 V1.1)Abemaciclib 150 / Anastrozol 1, Mammakarzinom, adjuvant (PID1785 V1.1)Abemaciclib 150 / Fulvestrant 500, Mammakarzinom, Zyklus 1 (PID1408 V1.1)Abemaciclib 150 / Fulvestrant 500, Mammakarzinom, Zyklus 2+ (PID1409 V1.1)Abemaciclib 150 / Letrozol 2,5, Mammakarzinom (PID566 V1.1)Abemaciclib 150 / Letrozol 2,5, Mammakarzinom, adjuvant (PID1786 V1.1)Alpelisib 300 / Fulvestrant 500, Mammakarzinom, Zyklus 1 (PID1620 V1.0)Alpelisib 300 / Fulvestrant 500, Mammakarzinom, Zyklus 2+ (PID1621 V1.0)Anastrozol 1 / Fulvestrant 500, Mammakarzinom (PID1248 V1.0)Anastrozol 1 / Mammakarzinom (PID1233 V1.0)Anastrozol 1, Mammakarzinom, adjuvant (PID1581 V1.0)Atezolizumab 1200, Mammakarzinom, adjuvant (PID2425 V1.0)Atezolizumab 840 / Bevazicumab 10 / Paclitaxel 90 - Atezolizumab 840 / Bevazicumab 10, Mammakarzinom, Erhaltung (PID3051 V1.0)Atezolizumab 840 / Bevazicumab 10 / Paclitaxel 90, Mammakarzinom (PID3050 V1.0)Atezolizumab 840 / Doxorubicin 60 / Cyclophosphamid 600, Mammakarzinom, neoadjuvant, Zyklus 4-5 (PID2424 V1.0)Atezolizumab 840 / Nab-Paclitaxel 100, Mammakarzinom (PID63 V1.0)Atezolizumab 840 / Nab-Paclitaxel 125, Mammakarzinom, neoadjuvant, Zyklus 1-3 (PID2423 V1.0)Avelumab 800, Mammakarzinom (PID66 V2.2)Bevacizumab 15 / Paclitaxel 80 / liposomales Doxorubicin 20 / Carboplatin 1,5, Mammakarzinom (PID754 V1.3)Capecitabin 1000 / Bevacizumab 15, Mammakarzinom (PID370 V1.3)Capecitabin 1000 / Docetaxel 75, Mammakarzinom, adjuvant (PID1643 V1.2)Capecitabin 1000 / Epirubicin 75 / Cyclophosphamid 500, Mammakarzinom, adjuvant (PID1644 V1.2)Capecitabin 1000 / Margetuximab 15, Mammakarzinom (PID1871 V1.0)Capecitabin 1000 / Paclitaxel 175, Mammakarzinom (PID380 V1.3)Capecitabin 1000, Mammakarzinom (PID2128 V1.0)Capecitabin 1250 / Docetaxel 75, Mammakarzinom (PID1685 V1.0)Capecitabin 1250, Mammakarzinom, adjuvant (PID1370 V1.1)Capecitabin 625, Mammakarzinom, adjuvant (PID2703 V1.0)Capivasertib 400 / Fulvestrant 500 / Goserelin 3,6, Mammakarzinom, Zyklus 1 (PID2609 V1.0)Capivasertib 400 / Fulvestrant 500 / Goserelin 3,6, Mammakarzinom, Zyklus 2+ (PID2610 V1.0)Carboplatin 150, Mammakarzinom (PID2374 V1.0)Carboplatin 5 / Cyclophosphamid 600, Mammakarzinom (PID101 V1.1)Carboplatin 6, Mammakarzinom (PID1940 V1.0)Catumaxomab (10/20/50/150), Peritonealkarzinose, sekundär (PID3037 V1.0)Cisplatin 30, Tumor, verschiedene Organe (PID2371 V1.0)Cisplatin 75 / Gemcitabin 1250, Mammakarzinom (PID763 V1.1)Cisplatin 75, Mammakarzinom (PID3101 V1.0)Clodronsäure (1040/520), Mammakarzinom, adjuvant (PID944 V1.0)CMF - Cyclophosphamid 100 / Methotrexat 40 / 5-Fluorouracil 600, Mammakarzinom (PID1153 V1.1)CMF - Cyclophosphamid 100 / Methotrexat 40 / Fluorouracil 600, Mammakarzinom, adjuvant, Variante 1 (PID1540 V1.3)CMF - Cyclophosphamid 600 / Methotrexat 40 / Fluorouracil 600, Mamma-Ca, adjuvant (PID100 V1.0)Cyclophosphamid 2000, Mammakarzinom, adjuvant, dosisdicht (PID401 V2.0)Cyclophosphamid 50 / Methotrexat 2,5, metastasiertes Mammakarzinom (PID83 V1.1)Cyclophosphamid 600 / liposomales Doxorubicin 60, Mammakarzinom (PID1686 V1.1)Cyclophosphamid 600 / liposomales Doxorubicin 75, Mammakarzinom (PID386 V1.0)Cyclophosphamid 600, Mammakarzinom, adjuvant, dosisdicht (PID1143 V1.1)Datopotamab Deruxtecan 6, Mammakarzinom (PID2955 V1.0)Docetaxel 100, Mamma-Ca, adjuvant (PID395 V1.1)Docetaxel 100, Mamma-Ca, neoadjuvant (PID405 V1.1)Docetaxel 100, Mammakarzinom (PID752 V1.0)Docetaxel 100, Mammakarzinom, adjuvant, Variante 1 (PID389 V1.1)Docetaxel 35, Mammakarzinom (PID753 V1.0)Docetaxel 75 / Carboplatin 5, Mammakarzinom (PID3100 V1.0)Docetaxel 75 / Carboplatin 6 / Trastuzumab (4/2), Mammakarzinom,adjuvant, Zyklus 1 (PID411 V1.0)Docetaxel 75 / Carboplatin 6 / Trastuzumab 2, Mammakarzinom, adjuvant, Zyklus 2+ (PID412 V1.0)Docetaxel 75 / Carboplatin 6 / Trastuzumab 6, Mammakarzinom, neoadjuvant, Zyklus 2+ (PID654 V1.2)Docetaxel 75 / Carboplatin 6 / Trastuzumab 8, Mammakarzinom, neoadjuvant, Zyklus 1 (PID655 V1.1)Docetaxel 75 / Carboplatin 6, Mammakarzinom (PID1664 V1.0)Docetaxel 75 / Cyclophosphamid 600, Mammakarzinom, adjuvant (PID393 V1.1)Docetaxel 75 / Gemcitabin 1000, Mammakarzinom (PID372 V1.0)Doxorubicin 20, Mammakarzinom (PID2131 V1.0)Doxorubicin 50 / Cyclophosphamid 500 / Docetaxel 75, Mammakarzinom, adjuvant (PID398 V1.0)Doxorubicin 50 / Cyclophosphamid 500 / Docetaxel 75, Mammakarzinom, neoadjuvant (PID593 V1.1)Doxorubicin 50 / Docetaxel 75, Mammakarzinom (PID378 V1.1)Doxorubicin 60 / Cyclophosphamid 600, Mamma-Ca, adjuvant (PID599 V1.1)Doxorubicin 60 / Cyclophosphamid 600, Mamma-Ca, adjuvant, dosisdicht (PID402 V1.1)Doxorubicin 60 / Cyclophosphamid 600, Mammakarzinom (PID381 V1.0)Doxorubicin 60 / Cyclophosphamid 600, Mammakarzinom, adjuvant, dosisdicht, Variante 1 (PID478 V1.1)Doxorubicin 60, Mammakarzinom, adjuvant, dosisdicht (PID1141 V1.1)Elacestrant 345, Mammakarzinom (PID2515 V0.1)Epirubicin 150, Mammakarzinom, adjuvant, dosisdicht (PID399 V2.0)Epirubicin 75 / Cyclophosphamid 600, Mammakarzinom (PID382 V1.1)Epirubicin 75 / Docetaxel 75, Mammakarzinom (PID379 V1.0)Epirubicin 90 / Cyclophosphamid 600, Mamma-Ca, adjuvant, dosisdicht (PID2702 V1.0)Epirubicin 90 / Cyclophosphamid 600, Mamma-Ca, neoadjuvant (PID404 V1.2)Epirubicin 90 / Cyclophosphamid 600, Mammakarzinom, adjuvant (PID579 V1.1)Epirubicin 90, Mammakarzinom (PID2130 V1.0)Epirubicin 90, Mammakarzinom, adjuvant, dosisdicht (PID86 V1.1)Eribulin 1,23 / Margetuximab 15, Mammakarzinom (PID1872 V1.1)Eribulin 1,23, Mammakarzinom (PID387 V1.0)Everolimus 10 / Exemestan 25, Mammakarzinom (PID371 V1.1)Everolimus 10 / Fulvestrant 500, Mammakarzinom, Zyklus 1 (PID1875 V1.0)Everolimus 10 / Fulvestrant 500, Mammakarzinom, Zyklus 2+ (PID1876 V1.0)Exemestan 25, Mammakarzinom, adjuvant (PID1582 V1.0)Fluorouracil 500 / Epirubicin 100 / Cyclophosphamid 500, Mammakarzinom, adjuvant (PID388 V1.1)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamid 600 / Trastuzumab 6 / Pertuzumab 420, Mammakarzinom, neoadjuvant, Zyklus 2-3 (PID1468 V1.1)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamid 600 / Trastuzumab 8 / Pertuzumab 840, Mammakarzinom, neoadjuvant, Zyklus 1 (PID1467 V1.0)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamid 600, Mammakarzinom, neoadjuvant, Zyklus 1-3 (PID1357 V1.0)Fluorouracil 600 / Epirubicin 90 / Cyclophosphamid 600 / Trastuzumab 6, Mammakarzinom, adjuvant (PID759 V1.1)Fulvestrant 500, Mammakarzinom (PID552 V1.1)Gemcitabin 1000 / Capecitabin 650, Mammakarzinom (PID1684 V1.0)Gemcitabin 1000 / Carboplatin 4 / Trastuzumab 6, Mammakarzinom, Zyklus 2+ (PID414 V1.0)Gemcitabin 1000 / Carboplatin 4 / Trastuzumab 8, Mammakarzinom, Zyklus 1 (PID413 V1.0)Gemcitabin 1000 / Carboplatin 4, Mammakarzinom (PID383 V1.0)Gemcitabin 1000 / Cisplatin 25, Mammakarzinom (PID3090 V1.0)Gemcitabin 1000 / Cisplatin 30, Mammakarzinom (PID1683 V1.1)Gemcitabin 1000 / Margetuximab 15, Mammakarzinom (PID1873 V1.0)Gemcitabin 1000 / Vinorelbin 25, Mammakarzinom (PID1682 V1.0)Gemcitabin 800, Mammakarzinom (PID2133 V1.0)Inavolisib 9 / Palbociclib 125 / Fulvestrant 500, Mammakarzinom, Zyklus 1 (PID2804 V1.0)Inavolisib 9 / Palbociclib 125 / Fulvestrant 500, Mammakarzinom, Zyklus 2+ (PID2805 V1.0)Lapatinib 1250 / Capecitabin 1000, Mammakarzinom (PID367 V1.2)Lapatinib 1500 / Fulvestrant (500/250), Mammakarzinom, Zyklus 1 (PID1770 V1.0)Lapatinib 1500 / Fulvestrant 250, Mammakarzinom, Zyklus 2+ (PID1771 V1.0)Lapatinib 1500 / Letrozol 2,5, Mammakarzinom (PID1772 V1.0)Letrozol 2,5, Mammakarzinom, adjuvant (PID1580 V1.0)Mitoxantron 12, Mammakarzinom (PID1424 V1.0)Nab-Paclitaxel 100 / Carboplatin 2 / Bevacizumab 10, Mamma-Ca (PID466 V1.1)Nab-Paclitaxel 100 / Cyclophosphamid 600 / Trastuzumab 6, Mammakarzinom, adjuvant Zyklus 2+ (PID410 V1.0)Nab-Paclitaxel 100 / Cyclophosphamid 600 / Trastuzumab 8, Mammakarzinom, adjuvant, Zyklus 1 (PID409 V1.0)Nab-Paclitaxel 100 / Cyclophosphamid 600, Mammakarzinom, adjuvant (PID58 V1.0)Nab-Paclitaxel 125 / Carboplatin 2, Mammakarzinom (PID61 V1.0)Nab-Paclitaxel 125 / Carboplatin 2, Mammakarzinom, neoadjuvant (PID1371 V1.0)Nab-Paclitaxel 125 / Trastuzumab (4/2), Mammakarzinom, Zykus 1 (PID427 V1.1)Nab-Paclitaxel 125 / Trastuzumab 2, Mammakarzinom, Zyklus 2+ (PID428 V1.1)Nab-Paclitaxel 125, Mammakarzinom (PID415 V1.1)Nab-Paclitaxel 125, Mammakarzinom, neoadj. (PID1354 V1.0)Nab-Paclitaxel 125, Mammakarzinom, Variante 1 (PID2512 V1.0)Nab-Paclitaxel 150, Mammakarzinom (PID114 V1.2)Nab-Paclitaxel 260, Mammakarzinom (PID98 V1.0)Neratinib 240 / Capecitabin 750, Mammakarzinom (PID1870 V1.0)Neratinib 240 / Fulvestrant 500, Mammakarzinom, Zyklus 1 (PID2713 V1.0)Neratinib 240 / Fulvestrant 500, Mammakarzinom, Zyklus 2+ (PID2714 V1.0)Neratinib 240, Mammakarzinom (PID1415 V1.1)Olaparib 300, Mammakarzinom (PID1105 V1.0)Olaparib 300, Mammakarzinom, adjuvant (PID2134 V1.0)Paclitaxel 100 / Carboplatin 2, Mammakarzinom (PID1961 V1.0)Paclitaxel 175 / Gemcitabin 1250, Mammakarzinom (PID377 V1.1)Paclitaxel 175, Mamma-Ca, adjuvant (PID396 V1.2)Paclitaxel 175, Mamma-Ca, adjuvant, dosisdicht (PID403 V1.2)Paclitaxel 175, Mammakarzinom (PID2132 V1.0)Paclitaxel 175, Mammakarzinom, adjuvant, dosisdicht, Variante 1 (PID479 V1.2)Paclitaxel 225, Mammakarzinom, adjuvant, dosisdicht (PID400 V2.0)Paclitaxel 80 / Carboplatin 2, Mammakarzinom (PID3099 V1.0)Paclitaxel 80 / Carboplatin 6, Mammakarzinom (PID1552 V1.1)Paclitaxel 80 / Trastuzumab 2, Mammakarzinom, adjuvant, Zyklus 2-12 (PID933 V1.1)Paclitaxel 80 / Trastuzumab 4, Mammakarzinom adjuvant, Zyklus 1 (PID932 V1.1)Paclitaxel 80, Mammakarzinom (PID2127 V1.0)Paclitaxel 80, Mammakarzinom, adjuvant (PID581 V1.2)Paclitaxel 90 / Bevacizumab 10, Mammakarzinom (PID120 V1.3)Palbociclib 125 / Exemestan 25 / Leuprorelin 3,75, Mammakarzinom (PID1532 V1.0)Palbociclib 125 / Fulvestrant 500, Mammakarzinom, Zyklus 1 (PID607 V1.0)Palbociclib 125 / Fulvestrant 500, Mammakarzinom, Zyklus 2+ (PID822 V1.0)Palbociclib 125 / Letrozol 2,5, Mammakarzinom (PID823 V1.0)Pegyliertes liposomales Doxorubicin 40, Mammakarzinom (PID914 V1.0)Pembrolizumab 200 / Carboplatin 2 / Gemcitabin 1000, Mammakarzinom (PID1933 V2.1)Pembrolizumab 200 / Doxorubicin 60 / Cyclophosphamid 600, Mamma-Ca, neoadjuvant, Zyklus 5-8 (PID1466 V1.1)Pembrolizumab 200 / Epirubicin 90 / Cyclophosphamid 600, Mamma-Ca, neoadjuvant, Zyklus 5-8 (PID1465 V1.2)Pembrolizumab 200 / Nab-Paclitaxel 100, Mammakarzinom (PID1930 V1.0)Pembrolizumab 200 / Paclitaxel 80 / Carboplatin 1,5, Mammakarzinom, neoadjuvant, Zyklus 1-4 (PID2717 V1.0)Pembrolizumab 200 / Paclitaxel 80 / Carboplatin 5, Mammakarzinom, neoadjuvant, Zyklus 1-4 (PID1464 V1.1)Pembrolizumab 200 / Paclitaxel 90, Mammakarzinom (PID1932 V1.0)Pembrolizumab 200, Mamma-Ca, adjuvant, Zyklus 9-17 (PID1868 V1.0)Pembrolizumab 200, Mammakarzinom, Erhaltung (PID1931 V1.0)Pembrolizumab 200, Mammakarzinom, Erstlinie (PID1324 V1.0)Pembrolizumab 200, Mammakarzinom, Zweitlinie (PID1329 V1.0)Pertuzumab 1200 / Trastuzumab 600 / Docetaxel 100, Mamma-Ca, adjuvant, Zyklus 1 (PID1751 V1.1)Pertuzumab 1200 / Trastuzumab 600 / Nab-Paclitaxel 125, Mammakarzinom, Zyklus 1 (PID1756 V1.1)Pertuzumab 1200 / Trastuzumab 600 / Paclitaxel 80, Mamma-Ca, adjuvant, Zyklus 1 (PID1753 V2.1)Pertuzumab 1200 / Trastuzumab 600 / Paclitaxel 80, Mammakarzinom, Zyklus 1 (PID1758 V1.1)Pertuzumab 420 / Trastuzumab 6 / Eribulin 1,23, Mammakarzinom, Zyklus 2+ (PID2871 V1.0)Pertuzumab 420 / Trastuzumab 6 / Anastrozol 1, Mammakarzinom, Zyklus 2+ (PID1500 V1.0)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75 / Carboplatin 6, Mammakarzinom, neoadjuvant, Zyklus 2-6 (PID1470 V2.1)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Mammakarzinom, adjuvant, Zyklus 2-4 (PID1166 V1.1)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Mammakarzinom, neoadjuvant, Zyklus 2-4, 4-6 oder 5-6 (PID750 V1.1)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Mammakarzinom, Zyklus 2+ (PID364 V1.2)Pertuzumab 420 / Trastuzumab 6 / Epirubicin 90 / Cyclophosphamid 600, Mammakarzinom, neoadj., Zyklus 5-8 (PID1410 V1.1)Pertuzumab 420 / Trastuzumab 6 / Letrozol 2,5, Mammakarzinom, adjuvant, Zyklus 2-9 (PID2442 V1.1)Pertuzumab 420 / Trastuzumab 6 / Letrozol 2,5, Mammakarzinom, neoadjuvant, Zyklus 2-4 (PID2434 V1.1)Pertuzumab 420 / Trastuzumab 6 / Letrozol 2,5, Mammakarzinom, Zyklus 2+ (PID1497 V1.1)Pertuzumab 420 / Trastuzumab 6 / Nab-Paclitaxel 125, Mammakarzinom, neoadj. Zyklus 2-4 (PID1356 V1.1)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80 / Carboplatin 6, Mammakarzinom, neoadjuvant, Zyklus 2-9 (PID2122 V1.1)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, Mammakarzinom, adj. Zyklus 2-4 (PID1168 V1.2)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, Mammakarzinom, neoadjuvant, Zyklus 2-4 (PID2432 V1.1)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, neoadjuvant, Zyklus 6-8 (PID3059 V1.0)Pertuzumab 420 / Trastuzumab 6 / Tamoxifen 20, Mammakarzinom, adjuvant, Zyklus 2-9 (PID2443 V1.1)Pertuzumab 420 / Trastuzumab 6 / Tamoxifen 20, Mammakarzinom, neoadjuvant, Zyklus 2-4 (PID2441 V1.1)Pertuzumab 420 / Trastuzumab 6 / Vinorelbin 30, Mammakarzinom, Zyklus 2+ (PID2712 V1.0)Pertuzumab 420 / Trastuzumab 6, Mammakarzinom, adjuvant (PID1350 V1.1)Pertuzumab 420 / Trastuzumab 6, Mammakarzinom, adjuvant, Zyklus 5-18 (PID680 V1.0)Pertuzumab 420, Mammakarzinom, Zyklus 2+ (PID2608 V1.0)Pertuzumab 600 / Trastuzumab 600 / Docetaxel 100, Mamma-Ca, adjuvant, Zyklus 2-4 (PID1752 V1.1)Pertuzumab 600 / Trastuzumab 600 / Nab-Paclitaxel 125, Mammakarzinom, Zyklus 2+ (PID1757 V1.2)Pertuzumab 600 / Trastuzumab 600 / Paclitaxel 80, Mamma-Ca, adjuvant, Zyklus 2-4 (PID1754 V1.1)Pertuzumab 600 / Trastuzumab 600 / Paclitaxel 80, Mammakarzinom, Zyklus 2+ (PID1759 V1.1)Pertuzumab 600 / Trastuzumab 600, Mamma-Ca, adjuvant, 5-18 (PID1755 V1.2)Pertuzumab 600 / Trastuzumab 600, Mammakarzinom (PID1760 V1.1)Pertuzumab 840 / Trastuzumab 6 / Paclitaxel 80, neoadjuvant, Zyklus 5 (PID3058 V1.0)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Mammakarzinom, Zyklus 1 (PID361 V1.2)Pertuzumab 840 / Trastuzumab 8 / Eribulin 1,23, Mammakarzinom, Zyklus 1 (PID2870 VV1.0)Pertuzumab 840 / Trastuzumab 8 / Vinorelbin 25, Mammakarzinom, Zyklus 1 (PID2711 V1.0)Pertuzumab 840 / Trastuzumab 8 / Anastrozol 1, Mammakarzinom, Zyklus 1 (PID1498 V1.0)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75 / Carboplatin 6, Mammakarzinom, neoadjuvant, Zyklus 1 (PID1469 V2.0)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Mammakarzinom, adjuvant, Zyklus 1 (PID1165 V1.1)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Mammakarzinom, neoadjuvant, Zyklus 1 oder Zyklus 4 (PID589 V1.2)Pertuzumab 840 / Trastuzumab 8 / Letrozol 2,5, Mammakarzinom, adjuvant, Zyklus 1 (PID2451 V1.1)Pertuzumab 840 / Trastuzumab 8 / Letrozol 2,5, Mammakarzinom, neoadjuvant, Zyklus 1 (PID2433 V1.1)Pertuzumab 840 / Trastuzumab 8 / Letrozol 2,5, Mammakarzinom, Zyklus 1 (PID1496 V1.0)Pertuzumab 840 / Trastuzumab 8 / Nab-Paclitaxel 125, Mammakarzinom, neoadj. Zyklus 1 (PID1355 V1.1)Pertuzumab 840 / Trastuzumab 8 / Paclitaxel 80, Mammakarzinom, adj. Zyklus 1 (PID1167 V1.2)Pertuzumab 840 / Trastuzumab 8 / Paclitaxel 80, Mammakarzinom, neoadjuvant, Zyklus 1 (PID2431 V1.1)Pertuzumab 840 / Trastuzumab 8 / Tamoxifen 20, Mammakarzinom, adjuvant, Zyklus 1 (PID2450 V1.1)Pertuzumab 840 / Trastuzumab 8 / Tamoxifen 20, Mammakarzinom, neoadjuvant, Zyklus 1 (PID2440 V1.1)Pertuzumab 840, Mammakarzinom, Zyklus 1 (PID2607 V1.0)Pertuzumab 840/ Trastuzumab 8/ Paclitaxel 80 / Carboplatin 6, Mammakarzinom, neoadjuvant, Zyklus 1 (PID2121 V1.0)Ribociclib 400 / Anastrozol 1 / Goserelin 3,6, Mammakarzinom, adjuvant (PID2585 V1.0)Ribociclib 400 / Letrozol 2,5 / Goserelin 3,6, Mammakarzinom, adjuvant (PID2578 V1.0)Ribociclib 600 / Fulvestrant 500, Mammakarzinom (PID73 V1.1)Ribociclib 600 / Letrozol 2,5 / Goserelin 3,6, Mammakarzinom (PID1372 V1.1)Ribociclib 600 / Letrozol 2,5, Mammakarzinom (PID127 V1.1)Sacituzumab Govitecan 10 / Pembrolizumab 200, Mammakarzinom (PID3011 V1.0)Sacituzumab Govitecan 10, Mammakarzinom (PID1780 V1.3)STUDIE - GAIN 2 - dtEC-dtD, Epirubicin 38-120 / Cyclophosphamid 450-1200, Mammakarzinom, Teil A (PID558 V1.0)STUDIE - GAIN-2 - dtEC-dtD, Docetaxel (60-100), Mammakarzinom, Teil B (PID559 V1.0)STUDIE - GAIN-2 - EnPC, Cyclophosphamid 2000, Mammakarzinom, Teil C (PID557 V1.0)STUDIE - GAIN-2 - Trastuzumab 6, Mammakarzinom (PID786 V1.0)STUDIE - GAIN-2 - Trastuzumab 8, Mammakarzinom (PID785 V1.0)Talazoparib 1, Mammakarzinom (PID1420 V1.0)Tamoxifen 20, Mammakarzinom, adjuvant (PID1583 V1.0)Thiotepa 15 / Hydrocortison 30, Tumor, verschiedene Organe (PID2372 V1.0)Topotecan 0,4, Meningeosis neoplastica (PID2520 V1.0)Trastuzumab (4/2) / Anastrozol 1, Mammakarzinom, Zyklus 1 (PID755 V1.0)Trastuzumab (4/2) / Docetaxel 75 / Cyclophosphamid 600, Mammakarzinom, adjuvant, Zyklus 1 (PID2721 V1.0)Trastuzumab 150, Meningeosis neoplastica (PID2523 V1.0)Trastuzumab 2 / Anastrozol 1, Mammakarzinom, Zyklus 2+ (PID756 V1.0)Trastuzumab 2 / Docetaxel 75 / Cyclophosphamid 600, Mammakarzinom, adjuvant, Zyklus 2+ (PID2722 V1.0)Trastuzumab 6 / Abemaciclib 150 / Fulvestrant 500, Mammakarzinom, Zyklus 2+ (PID1602 V1.1)Trastuzumab 6 / Docetaxel 100, Mammakarzinom, Zyklus 2+ (PID417 V1.0)Trastuzumab 6 / Lapatinib 1000 / Letrozol 2,5, Mammakarzinom, Zyklus 2+ (PID1769 V1.0)Trastuzumab 6 / Letrozol 2,5, Mammakarzinom, Zyklus 2+ (PID765 V1.0)Trastuzumab 6 / Vinorelbin 30, Mammakarzinom, Zyklus 2+ (PID419 V1.0)Trastuzumab 6, Mammakarzinom, adjuvant (PID1474 V1.1)Trastuzumab 6, Mammakarzinom, adjuvant, Zyklus 2+, Variante 1 (PID1688 V1.1)Trastuzumab 6, Mammakarzinom, Zyklus 2+ (PID760 V1.1)Trastuzumab 600, Mammakarzinom (PID1330 V1.0)Trastuzumab 8 / Abemaciclib 150 / Fulvestrant 500, Mammakarzinom, Zyklus 1 (PID1601 V1.1)Trastuzumab 8 / Docetaxel 100, Mammakarzinom, Zyklus 1 (PID416 V1.0)Trastuzumab 8 / Lapatinib 1000 / Letrozol 2,5, Mammakarzinom, Zyklus 1 (PID1768 V1.0)Trastuzumab 8 / Letrozol 2,5, Mammakarzinom, Zyklus 1 (PID764 V1.0)Trastuzumab 8 / Vinorelbin 30, Mammakarzinom, Zyklus 1 (PID418 V1.0)Trastuzumab 8, Mammakarzinom, adjuvant, Zyklus 1, Variante 1 (PID1687 V1.1)Trastuzumab 8, Mammakarzinom, Zyklus 1 (PID761 V1.1)Trastuzumab 80, Meningeosis neoplastica, Zyklus 1 (PID2526 V1.0)Trastuzumab 80, Meningeosis neoplastica, Zyklus 2 (PID2527 V1.0)Trastuzumab 80, Meningeosis neoplastica, Zyklus 3+ (PID2542 V1.0)Trastuzumab Deruxtecan 5,4 / Pertuzumab 420, Mammakarzinom, Zyklus 2+ (PID3002 V1.0)Trastuzumab Deruxtecan 5,4 / Pertuzumab 840, Mammakarzinom, Zyklus 1 (PID3001 V1.0)Trastuzumab Deruxtecan 5,4 Mammakarzinom, adjuvant (PID3089 V1.0)Trastuzumab Deruxtecan 5,4 Mammakarzinom, neoadjuvant, Zyklus 1-4 (PID3057 V1.0)Trastuzumab Deruxtecan 5,4, Mammakarzinom (PID1634 V1.1)Trastuzumab Emtansin 3,6, Mammakarzinom, adjuvant (PID1343 V1.0)Trastuzumab Emtansin 3,6, Mammakarzinom, Drittlinie (PID366 V1.0)Trastuzumab Emtansin 3,6, Mammakarzinom, Zweitlinie (PID365 V1.1)Trastuzumab-Emtansin 3,6, Mammakarzinom, neoadjuvant (PID111 V1.0)Trofosfamid 150, Mammakarzinom (PID430 V1.1)Trofosfamid 50, Mammakarzinom (PID429 V1.1)Tucatinib 300 / Capecitabin 1000 / Trastuzumab 6, Mammakarzinom, Zyklus 2+ (PID1762 V1.1)Tucatinib 300 / Capecitabin 1000 / Trastuzumab 600, Mammakarzinom (PID1763 V1.1)Tucatinib 300 / Capecitabin 1000 / Trastuzumab 8, Mammakarzinom, Zyklus 1 (PID1761 V1.1)Vinorelbin 25 / Capecitabin 1000 - Capecitabin 1000 Erhaltung, Mammakarzinom (PID1693 V1.0)Vinorelbin 25 / Capecitabin 1000, Mammakarzinom (PID1692 V1.0)Vinorelbin 25, Mammakarzinom (PID2129 V1.0)Vinorelbin 30 / Fluorouracil 750, Mammakarzinom (PID678 V1.0)Vinorelbin 30 / Margetuximab 15, Mammakarzinom (PID1874 V1.0)Vinorelbin 30, Mammakarzinom (PID739 V1.0)Vinorelbin 40 / Cyclophosphamid 50 / Capecitabin 500, Mammakarzinom (PID1377 V1.1)Vinorelbin 60 / Capecitabin 1000, Mammakarzinom, Zyklus 1 (PID942 V1.2)Vinorelbin 70, Mammakarzinom (PID420 V1.2)Vinorelbin 80 / Capecitabin 1000, Mammakarzinom, Zyklus 2+ (PID943 V1.2)Zoledronsäure 4, Mammakarzinom, adjuvant (PID928 V1.1)Zoledronsäure 4, Mammakarzinom, adjuvant, Variante 1 (PID935 V1.1)
